STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma

  • Cancer Immunol Immunother. 2022 Nov 27. doi: 10.1007/s00262-022-03336-9.
Hao Cui  1 Zhou Lan  1 Ke-Long Zou  1 Yu-Yue Zhao  2 Guang-Tao Yu  3
Affiliations
  • 1. Stomatological Hospital, Southern Medical University, No. 366, Jiangnan Road, Haizhu Region, Guangzhou City, 510280, China.
  • 2. Stomatological Hospital, Southern Medical University, No. 366, Jiangnan Road, Haizhu Region, Guangzhou City, 510280, China. [email protected].
  • 3. Stomatological Hospital, Southern Medical University, No. 366, Jiangnan Road, Haizhu Region, Guangzhou City, 510280, China. [email protected].
Abstract

Myeloid-derived suppressor cells (MDSCs) are one of the tumor-infiltrating immune cell population, which play a powerful role in inhibiting anti-tumor immune response. Our previous studies have shown that STAT3 blockade can decrease the number of MDSCs in tumor microenvironment. However, it is unclear for the molecular mechanism of down-regulation MDSCs with STAT3 Inhibitor. In this study, we first detected and analyzed the expression of p-STAT3, CD33, CD14, CD39 and CD73 via oral squamous cell carcinoma (OSCC) tissue array. We found that p-STAT3 was positively correlated with CD14, CD33, CD39, and CD73 in OSCC patient specimens. Then we found STAT3 blockade with S3I-201 reduced the expression of CD39/CD73 and the synthesis of adenosine, as well as inhibiting monocytes to MDSCs differentiation in vitro. Furthermore, we found that S3I-201 displayed prominent anti-tumor efficacy in C3H/He OSCC mouse model via inhibiting CD39/CD73-adenosine signal pathway and decreasing MDSCs. These results suggest that STAT3 signal can induce the differentiation of monocytes into MDSCs in tumor microenvironment depending on CD39/CD73-adenosine signal pathway and STAT3 blockade is a promising therapeutic strategy for OSCC.

Keywords
Adenosine; Monocytes; Myeloid-derived suppressor cells; Oral squamous cell carcinoma; STAT3.
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • 98.35%, STAT3 Inhibitor
    target: STAT
    Research Areas: Cancer